CVDefine ® (Anti-Phosphorylcholine) ELISA

pCVDefine reg; br /
(Anti-Phosphorylcholine) ELISA/p
pimg alt=For Research Use Only src=http://www.alpco.com/img/ruo.gif align=absMiddle / For Research Use Only/p
div class=prod_head_infohr /
/div
div class=prod_spec_box
div class=prod_specbFormat:/b/div
div class=prod_spec_infoELISA / EIA/div
/div
div class=prod_spec_box
div class=prod_specSample Type:/div
div class=prod_spec_infoserum, plasma/div
/div
div class=prod_spec_box
div class=prod_specbSample Size:/b/div
div class=prod_spec_info10 micro;l/div
/div
div class=prod_spec_box
div class=prod_specbSize:/b/div
div class=prod_spec_info96 wells/div
/div
div class=prod_spec_box
div class=prod_specbRange:/b/div
div class=prod_spec_info0.6 - 100 U/ml/div
/div
div class=prod_spec_box
div class=prod_specbSensitivity:/b/div
div class=prod_spec_info0.5 U/ml/div
/div
div class=prod_spec_box
div class=prod_specbIncubation Time:/b/div
div class=prod_spec_info1 hour/div
div class=prod_spec_info
pbSummary:/b/p
Inflammation plays a key role in the development and progression of arthrosclerosis. The inflammatory reaction is characterized by activation of immune competent cells in the arterial wall. Low density lipoprotein (LDL) has been shown to be a major risk factor for cardiovascular disease. Oxidized LDL (OxLDL) is taken up by specific receptors on macrophages resulting in build-up of atherosclerotic plaques. OxLDL has been shown to have proinflammatory properties and can activate T-cells and macrophages. Antibodies directed against oxidized LDL are a hallmark of atherosclerosis and immunization to OxLDL has been shown to reduce athrosclerosis. One of the major epitopes responsible for the immune reaction in LDL has been identified as phosphorylcholine (PC). Natural antibodies against PC are common from early age and their clinical role in development of cardiovascular disease (CVD) offers a novel approach to improved understanding of the disease./div
/div